(2000). A comparison of HIV risk behaviors between new and longterm injection drug users. Subst Alcohol Actions Misuse
(1998). A sterile syringe for every drug user injection: how many injections take place annually, and how might pharmacists contribute to syringe distribution? J Acquir Immune Defic Syndr Hum Retrovirol
(2007). Access and coverage of needle and syringe programmes (NSP)
(2008). Access to syringes in three Russian cities: implications for syringe distribution and coverage.
(2005). AJ: Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ
(1995). Alter MJ: Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program.
(1999). Attitudinal factors associated with community pharmacists' involvement in services for drug misusers. Addiction
(1998). Biberfeld G: Evaluation of 14 commercial HIV-1/HIV-2 antibody assays using serum panels of different geographical origin and clinical stage including a unique seroconversion panel.
Boborova N: HIV and risk behaviour among injecting drug users in two cities (Tallinn, Kohtla-Järve) in Estonia.
CE: Individual and structural influences shaping pharmacists' decisions to sell syringes to injection drug users in Atlanta,
(2004). DD: Sampling and estimation in hidden populations using respondent-driven sampling. Sociol Methodol
(2008). Des Jarlais D: High-prevalence and highestimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs. J Public Health (Oxf)
(2001). Estonian Drug Monitoring Centre National Focal Point: National Report on Drug Situation in Estonia
(2002). Extensions of Respondent-Driven Sampling: A New Approach to the Study of Injection Drug Users Aged 18–25. AIDS Behav
(2005). FI: The role of "long-term" and "new" injectors in a declining HIV/AIDS epidemic in Rio de Janeiro, Brazil. Subst Use Misuse
(1996). Friedman SR: HIV incidence among injecting drug users in New York City syringe- exchange programmes. Lancet
(2000). Friedman SR: HIV incidence among injection drug users in New York City, 1992–1997: evidence for a declining epidemic.
(2004). G: Estimating injection drug use prevalence using state wide administrative data sources: Estonia,
(1996). Glanz A: Role of community pharmacies in relation to HIV prevention and drug misuse: findings from the 1995 national survey in England and Wales. BMJ
(2007). High hepatitis C incidence in new injecting drug users: a policy failure?
(2007). High prevalence of blood-borne virus infections and high-risk behaviour among injecting drug users in Tallinn, Estonia.
(1997). HIV prevention and drug treatment services for drug misusers: a national study of community pharmacists' attitudes and their involvement in service specific training. Addiction
(2003). Injecting behaviour of injecting drug users at needle and syringe programmes and pharmacies in Australia. Int J Drug Policy
(1998). Multicenter evaluation of the new automated
(1999). Neaigus A: Risk behavior and HIV infection among new drug injectors in the era of AIDS in New York City. J Acquir Immune Defic Syndr Hum Retrovirol
(2001). Obadia Y: Multiple access to sterile syringes for injection drug users: vending machines, needle exchange programs and legal pharmacy sales in Marseille, France. Eur Addict Res
(1997). Olinto MT: The role of conceptual frameworks in epidemiological analysis: a hierarchical approach.
(2002). Pharmacist support for selling syringes without a prescription to injection drug users in Rhode Island. J Am Pharm Assoc (Wash)
(1996). Prescribing injectable and oral methadone to opiate addicts: results from the 1995 national postal survey of community pharmacies in England and Wales. BMJ
(2002). Respondent driven sampling II: deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl
(1997). Respondent driven sampling: A new approach to the study of hidden population. Soc Probl
(2005). StataCorp: Stata Statistical Software: Relase 9. College Station, TX: Stata Corp LP;
The Centralized Information System for Infectious Diseases [http://data.euro.who.int/cisid/]
(2006). Treloar C: Comparison of needle and syringe programme attendees and non-attendees from a high drugusing area in Sydney, New South Wales. Drug Alcohol Rev
(2002). TW: Pharmacists' attitudes and concerns regarding syringe sales to injection drug users in Denver,
(2007). Uusküla A: The HIV prevention needs of injection drug users in Estonia.
(2004). Vlahov D: Explaining the relationship between race/ethnicity and pharmacy purchased syringes among injection drug users in New York City. Ethn Dis
(2003). Vlahov D: Impact of expanding syringe access in New York on sources of syringes for injection drug users in Harlem and the Bronx,
(2000). Vlahov D: New York City pharmacists' attitudes toward sale of needles/syringes to injection drug users before implementation of law expanding syringe access. J Urban Health
(2006). WHO Phase II Drug Injection Collaborative Study Group: Using standardized methods for research on HIV and injecting drug use in developing/transitional countries: case study from the WHO Drug Injection Study Phase II. BMC Public Health